Millennium Management
ANTX icon

Millennium Management’s AN2 Therapeutics ANTX Stock Holding History

Millennium Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.6M Buy
2,222,502
+2,126,819
+2,223% +$4.39M ﹤0.01% 2462
2025
Q4 		$109K Buy
+95,683
New +$112K ﹤0.01% 5619
2025
Q2 		– Sell
-50,038
Closed -$68.1K – 5831
2025
Q1 		$68.1K Sell
50,038
-159,328
-76% -$201K ﹤0.01% 5495
2024
Q4 		$289K Sell
209,366
-188,559
-47% -$229K ﹤0.01% 5095
2024
Q3 		$426K Sell
397,925
-128,427
-24% -$223K ﹤0.01% 4953
2024
Q2 		$1.13M Buy
526,352
+429,438
+443% +$1.02M ﹤0.01% 4015
2024
Q1 		$315K Buy
96,914
+57,240
+144% +$623K ﹤0.01% 5106
2023
Q4 		$813K Buy
+39,674
New +$664K ﹤0.01% 4313
2023
Q3 		– Sell
-24,242
Closed -$206K – 6084
2023
Q2 		$206K Buy
+24,242
New +$174K ﹤0.01% 5100
2022
Q2 		– Sell
-74,238
Closed -$1.12M – 6931
2022
Q1 		$1.12M Buy
+74,238
New +$1.13M ﹤0.01% 4421

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management's ANTX Position: Q1 2026 in Review

Millennium Management increased its AN2 Therapeutics (ANTX) stake by 2,223% in Q1 2026, buying an estimated $4.39M and bringing the position to 2,222,502 shares worth $7.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2462.

Millennium Management first reported a position in ANTX in Q1 2022 and has held it in 10 quarters since. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Millennium Management held 2,222,502 shares of AN2 Therapeutics worth $7.6M as of Q1 2026.
  • Millennium Management bought 2,126,819 AN2 Therapeutics shares in Q1 2026, an estimated $4.39M.
  • AN2 Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2462 holding.
  • Millennium Management first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.